In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Rising Leaders Leadership Immune Disorders

The Importance Of Mentorship: Turning Scientists Into Leaders

  • Interviews

Executive Summary

Merck’s head of clinical immunology and 2022 Rising Leader Aileen Pangan is empowering researchers to become leaders through a highly tailored and honest approach to mentorship.

You may also be interested in...



Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies

Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.

Executives On The Move: Roche, Vanda Pharmaceuticals And More

Recent executive changes in the industry include C-suite changes at Roche and Quince Therapeutics. Meanwhile, new directors were appointed at Vanda Pharmaceuticals and MAIA Biotechnology.

Table

View full table

Topics

Related Companies

Tags:
Rising Leaders Leadership Immune Disorders
Latest Headlines

The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge

Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

How To Develop A Patient-First Strategy For CGT Commercialization

Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target

See All
UsernamePublicRestriction

Register

IV125073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By